Aktiesnakken — Juni 2012
-
Det tror jeg ikke
-
øv en træls dag med topo data. Misset primært endpoint er aldrig en god ting. Det betyder som minimum at der skal laves et nyt forsøg
-
spørgsmålet er om de måske vil forsøge en anden combi behandling eller indikationen ligefrem droppes?
-
Topo har jo ikke mange penge på kistebunden
-
nogen der ved om der var tilknyttet en sspi milestones til dette forsøg?
-
var der ikke
-
milestones er ved PTCL
-
Topo får 200 millioner kroner i 2013
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind